MASTL and breast carcinoma: Interestingly, overexpression of mitotic genes along with high levels of CIN are linked with resistance to paclitaxel in breast cancer (Swanton et al., 2009), suggesting that overexpressed MASTL could potentially be used as a biomarker for resistance to paclitaxel and other mitotic chemotherapies.